跳至主要内容
临床试验/NCT00197379
NCT00197379Unknown不适用

The Study for New Effect of Roxithromycin on Androgenetic Alopecia.

Hamamatsu University2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2005年5月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
发起方
入组人数
20
试验地点
2

研究概览

简要总结

The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects. We firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro. Therefore, we apply this drug on this disease therapy.

详细描述

The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Androgenetic alopecia

排除标准

  • Cicatricial alopecia
  • Allergy to roxitromycin
  • Children (19years old or younger)
  • Pregnant female

研究者

发起方
Hamamatsu University
申办方类型
Other

研究点 (2)

Loading locations...

相似试验